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liver cirrhosis is seldom reported. This study aimed to assess the efficacy of 7-day standard tri-
ple therapy in patients with CLD including cirrhosis and to investigate the clinical factors influ-
encing the success of eradication. A total of 592 H. pylori-infected patients, who received 7-
day standard first-line triple therapy between January 1, 2014, and December 31, 2014, were
recruited. Patients were divided into two groups: CLD group (NZ 136) and non-CLD group
(NZ 456). The eradication rates attained by the CLD and non-CLD groups were 86.0% and
84.2%, respectively, in the per-protocol analysis (pZ 0.606). The eradication rates of liver
cirrhosis and noncirrhosis CLD were 88.5% and 84.3%, respectively (pZ 0.783). The adverse
events were similar between the two groups (8.8% vs. 9.2%, pZ 0.891). Compliance between
the two groups was good (99.3% vs. 99.6%, pZ 0.670). The univariate analysis showed male sex
to be the significant clinical factor in the non-CLD group (pZ 0.001) and alcohol consumption
to be the significant clinical factor influencing H. pylori eradication rate in patients with CLD
(pZ 0.022). Alcohol consumption was the only significant factor influencing H. pylori eradica-
tion in multivariate analysis (odds ratioZ 3.786, pZ 0.031). The results of this study suggest
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Helicobacter pylori infection is one of the most common
bacterial infections in the world [1]. This pathogen is the
major risk factor in peptic ulcer disease and it could slowly
induce chronic gastritis, which progresses through the
premalignant stages of atrophic gastritis, intestinal meta-
plasia, and dysplasia, and then finally to gastric cancer
[2,3]. Fortunately, successful eradication of H. pylori has
greatly reduced the recurrence of peptic ulcers and gastric
cancers [4e6]. Recent studies have explored the significant
association between this bacterium and extragastric dis-
eases such as cardiovascular disease, metabolic syndrome,
and some liver diseases such as nonalcoholic fatty liver
disease, nonalcoholic steatohepatitis, liver fibrosis, and
cirrhosis [7]. The possibly related pathogenesis is chronic
inflammation and immune responses at the local and sys-
temic level [8].
Current evidence to correlate H. pylori infection and
chronic liver diseases (CLDs) is still inconsistent, and
therefore this is an area worth further investigation. One
of the etiologies of CLD is viral infections. Taiwan is an
endemic area for chronic hepatitis B virus (HBV) and
chronic hepatitis C virus (HCV) infections, which are
mostly transmitted perinatally. The prevalence rates of
hepatitis B and hepatitis C in Taiwan’s general population
are approximately 8% and 4%, respectively [9,10]. Those
infected individuals are at an increased risk of developing
hepatic decompensation, cirrhosis, and hepatocellular
carcinoma. When the infection progresses to the cirrhotic
stage, patients with peptic ulcer bleeding have a fivefold
higher risk of complications or death [11]. H. pylori
infection in the stomach of cirrhosis patients has a sig-
nificant association with hyperammonemia [12], portal
hypertension [13], and peptic ulcer disease. The preva-
lence rate of H. pylori infection in cirrhotic patients with
peptic ulcers varied between 43% and 95%, which was
higher than that reported in the general population
[14e17]. Early identification and eradication of H. pylori
infection are associated with a lower risk of recurrent
peptic ulcers in cirrhotic patients, according to a Taiwan
population-based study [18]. The metabolism of certain
drugs such as proton-pump inhibitor (PPI) and antibiotics
could be altered in patients with CLD. However, whether it
makes a difference in the result of H. pylori eradication
rate and adverse events of triple therapy require further
studies.
To our knowledge, only limited reports are available on
H pylori eradication among patients with CLD. This study
aimed to assess the efficacy of 7-day standard triple ther-
apy in patients with CLD including cirrhosis and to investi-
gate the clinical factors influencing the success of
eradication.Methods
Patients
A total of 784 H. pylori-infected patients who received
standard first-line triple therapy (PPI twice daily, 500 mg
clarithromycin twice daily, and 1 g amoxicillin twice daily
for 7 days) were retrospectively studied between January
1, 2014, and December 31, 2014, at outpatient clinics in
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung,
Taiwan. Eventually, 592 patients were recruited into the
per-protocol (PP) study after we strictly excluded 192 pa-
tients with incomplete chart recording. All patients were at
least 18 years of age and had received endoscope exami-
nations that showed either peptic ulcers or gastritis. Pa-
tients were then divided into two groups: CLD group and
non-CLD group.
Patients with CLDs were defined as follows: having a
medical history of hepatitis B and/or hepatitis C, with
abnormal results in liver function tests for at least 6 months,
and/or with liver cirrhosis. The diagnosis of cirrhosis was
confirmed by clinical, laboratory, abdominal ultrasono-
graphic, or histological findings [19]. Diagnosis of HBV- or
HCV-related liver disease was determined using specific viral
markers (HBsAg or anti-HCV). Alcohol-related liver disease
was defined as daily alcohol consumption over 80 g in men
and over 40 g in women for at least 10 years with negative
viral, metabolic, and autoimmune markers [20].
The confirmation of H. pylori eradication failure was
defined as patients with either one positive 13C-UBT or any
two positive results of the rapid urease test, histology, and
culture after first-line eradication therapy. According to our
hospital requirements, all registered patients were fol-
lowed up to assess drug compliance and adverse effects as
soon as they finished their medications. Then, these pa-
tients underwent either an endoscopy or a urea breath test
4e8 weeks later. Poor compliance was defined as failure to
finish 80% of all medication due to adverse effects [21].
Demographic data including age, sex, social history of
smoking, alcohol consumption, previous peptic ulcer his-
tory, laboratory data (aspartate transaminase, alanine
transaminase, total bilirubin, albumin, blood urea nitrogen,
creatinine, and prothrombin time) were collected via
electrical medical records. This study was approved by both
the Institutional Review Board and the Ethics Committee of
Chang Gung Memorial Hospital (IRB 201600030B0D001). The
Ethics Committee waived the requirement for informed
consent, and each patient’s medical records were anony-
mized and deidentified prior to access. All patients pro-
vided their written informed consent before endoscopic
interventions. None of our patients belonged to the minors/
children age groups.
Table 1 Demographic data and endoscopic findings of the
two patient groups.
CLD
(including LC)
(n Z 136)
Control
non-CLD
(n Z 456)
p
Age (y) 57.1  11.3 58.5  12.4 0.272
Sex (male/female) 68/68 237/219 0.686
Smoking 16 (11.8) 70 (15.4) 0.426
Alcohol consumption 15 (11.0) 75 (16.4) 0.231
Previous history of
peptic ulcer
10 (7.4) 60 (13.2) 0.069
Endoscopic findings 0.543
Gastritis 44 (33.3) 132 (29.1)
Gastric ulcer 40 (30.3) 161 (35.5)
Duodenal ulcer 36 (27.3) 110 (24.3)
Gastric and
duodenal ulcer
12 (9.1) 50 (11.0)
Category of CLDs
Hepatitis B 98 (72.0)
Hepatitis C 34 (25.0)
Cryptogenic 8 (5.9)
Laboratory data
Aspartate
transaminase (U/L)
31.6  16.9 25.1  11.2 <0.001
Alanine
transaminase (U/L)
32.7  25.2 26.5  16.5 0.002
Total bilirubin
(mg/dL)
0.9  0.5 1.0  1.6 0.447
Albumin (g/dL) 4.3  0.4 4.5  0.4 0.072
Blood urea
nitrogen (mg/dL)
17.6  24.3 16.3  12.3 0.579
Creatinine (mg/dL) 1.1  1.3 1.2  1.6 0.581
Prothrombin
time (s)
10.7  1.5 10.5  1.1 0.336
Data are presented as n (%) or mean  standard deviation.
CLD Z chronic liver disease; LC Z liver cirrhosis.
Table 2 Major outcomes of eradication therapy.
Eradication rate
CLD Non-CLD p
Per-protocol
analysis
86.0 (117/136) 84.2 (384/456) 0.606
Adverse event 8.8 (12/136) 9.2 (42/456) 0.891
Compliance 99.3 (135/136) 99.6 (454/456) 0.670
Data are presented as % (n/N ).
CLD Z chronic liver disease.
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The primary outcome variables were the eradication rate,
presence of adverse events, and level of patient compli-
ance. Using the SPSS program (version 18; SPSS Inc., Chi-
cago, IL, USA), Chi-square tests with or without Yates’
correction for continuity and Fisher’s exact tests were used
when appropriate to compare the major outcomes between
groups. Eradication rates were analyzed by PP approaches.
The PP analysis excluded patients with unknown H. pylori
status following therapy and those with major protocol vi-
olations. A p value < 0.05 was considered statistically sig-
nificant. To determine the independent factors that
affected treatment response, the clinical and laboratory
parameters were analyzed by univariate and multivariate
analyses.
Results
The demographic data of the two groups are summarized in
Table 1. The eradication rates attained by the CLD and non-
CLD groups were 86.0% (117/136) and 84.2% (384/456),
respectively, in the PP analysis (p Z 0.606). The eradica-
tion rate was 88.5% (23/26) in liver cirrhosis patients and
84.5% (93/110) in noncirrhosis CLD patients (p Z 0.783).
Adverse events and compliance
The adverse events were similar between the two groups
(8.8% vs. 9.2%, p Z 0.891; Table 2). These adverse events
included abdominal pain, constipation, diarrhea, dizziness,
headache, nausea/vomiting, and skin rash. In the CLD
group, one patient (0.7%) had mild diarrhea, nine patients
(6.6%) had abdominal pain, and two patients (1.5%) had
constipation. In the non-CLD group, 12 patients (2.6%) had
mild diarrhea, 13 patients (2.9%) had abdominal pain, six
patients (1.3%) had constipation, four patients (0.9%) had
nausea, six patients (1.3%) had headache or dizziness, and
one patient (0.2%) had rash. However, these adverse events
were mild and did not disturb the patients’ daily activities.
Both groups had good drug compliance (99.3% in the CLD
group vs. 99.6% in the non-CLD group, p Z 0.670).
Factors influencing the efficacy of anti-H. pylori
therapy
Results of univariate analysis showed that male sex was the
significant clinical factor in the non-CLD group (89.5% vs.
78.5%, p Z 0.001) and alcohol consumption was the sig-
nificant clinical factor influencing H. pylori eradication rate
in patients with CLD (66.7% vs. 88.4%, pZ 0.022; Table 3).
Alcohol consumption was the only significant factor influ-
encing H. pylori eradication in CLD patients during multi-
variate analysis (odds ratio Z 3.786; 95% confidence
interval Z 1.126e12.690, p Z 0.031; Table 4).
Discussion
H. pylori is a Gram-negative bacterium that causes many
diseases, such as chronic gastritis, peptic ulcer disease,gastric mucosa-associated lymphoid tissue lymphoma, and
gastric cancer [7]. Recent studies have examined the
importance of H. pylori infection in the diseases outside
the stomach and explored the significance of this bacterium
in the pathogenesis of some metabolic and cardiovascular
diseases [22]. Some authors suggest that H. pylori infection
can cause other disorders, including CLDs such as nonal-
coholic fatty liver diseases, nonalcoholic steatohepatitis,
liver fibrosis, cirrhosis, and even hepatic carcinoma [23].
Table 3 Univariate analysis of the clinical factors influencing the efficacy of Helicobacter pylori eradication.
Principle parameter CLD (nZ 136) Non-CLD (nZ 456)
Case No. Eradication
rate (%)
p Case No. Eradication
rate (%)
p
Age (y) <50 35 94.3 0.149 106 84.9 0.842
50 101 83.2 350 84.0
Sex Female 68 83.8 0.458 219 78.5 0.001
Male 68 88.2 237 89.5
Smoking () 120 86.7 0.557 386 83.2 0.149
(þ) 16 81.3 70 90.0
Alcohol consumption () 121 88.4 0.022 380 83.2 0.181
(þ) 15 66.7 75 89.3
Previous history of peptic ulcer () 126 87.2 0.132 396 84.3 0.842
(þ) 10 70.0 60 83.3
Compliance Good 135 85.9 0.686 453 84.5 0.179
Poor 1 100 2 50.0
Etiology of liver diseases
Hepatitis B Hepatitis B virus 98 87.8 0.443
Non-B 38 84
Hepatitis C Hepatitis C virus 34 82.4 0.627
Non-C 102 84.9
Cryptogenic NBNC 8 75 0.310
Else 128 86.7
Cirrhosis LC 26 88.5 0.783
Non-LC 110 84.5
Laboratory data
Aspartate transaminase (U/L) >40 23 91.3 0.736 18 94.4 0.486
<40 102 87.3 283 86.6
Alanine transaminase (U/L) >40 29 93.1 0.360 55 85.5 >0.99
<40 104 84.6 310 85.2
Total bilirubin (mg/dL) >2 4 75 0.436 9 77.8 0.619
<2 110 87.3 216 86.1
Albumin (mg/dL) <3.5 6 83.3 0.535 3 100 >0.99
>3.5 55 89.1 124 86.3
Blood urea nitrogen (mg/dL) >20 10 80.0 0.274 34 97.1 0.087
<20 48 91.7 173 86.1
Creatinine (mg/dL) >1.5 8 87.5 >0.99 26 92.3 0.396
<1.5 94 88.3 319 84.6
Prothrombin time (s) >14 1 100 >0.99 1 100 >0.99
<14 69 82.6 190 85.3
CLD Z chronic liver disease; LC Z liver cirrhosis; NBNC Z non-B, non-C cirrhosis.
Table 4 Multivariate analysis of the clinical factors
influencing the efficacy of Helicobacter pylori eradication
in chronic liver diseases.
Clinical
factor
Coefficient Standard
error
Odds
ratio
(95% CI)
p
Alcohol
consumption
1.331 0.617 3.786
(1.126e12.690)
0.031
CI Z confidence interval.
400 C.-E. Tsai et al.The prevalence of ulcers of the stomach and/or duo-
denum caused by H. pylori is higher in patients suffering
from liver cirrhosis [14]. The most important pathogenesis
factor of gastroduodenal lesions in end-stage liver diseaseand cirrhosis is portal hypertension. It could be due to
splenic congestion, which interferes with the normal
reparative processes of the gastroduodenal mucosa and
leads to increased susceptibility to acid and pepsin secre-
tion [24]. Eradication therapy may be beneficial for
cirrhotic patients because it diminishes the risk of recurrent
peptic ulcers and bleeding [19]. Miyaji and colleagues [12]
discovered that the eradication of H. pylori was effective
in patients with diffuse H. pylori infection in the stomach
who also had hyperammonemia.
The clinical reports on H. pylori eradication in CLD are
limited in the literature and the results were inconsistent.
In our study, the eradication rates attained by the CLD and
non-CLD groups were 86.0% and 84.2%, respectively, in the
PP analysis (p Z 0.606). This was similar between cirrhotic
patients and noncirrhotic CLD patients (88.5% vs. 84.5%,
p Z 0.783). However, the number of patients with liver
H. pylori eradication and chronic liver disease 401cirrhosis was only 26 in this study, which is too small for
subgroup analysis such as the disease severity stage and
ChildePugh score. Of note, the H. pylori eradication rates
in patients with CLD were comparable to those with non-
CLD in this study. Interestingly, Furusyo and colleagues
[25] reported successful eradication rates of 91.0% for HCV-
infected patients and 72.8% for HCV-uninfected controls,
which was significantly higher, by intention-to-treat anal-
ysis. This could possibly be explained by the role of liver
disease in the metabolism of PPI. HCV infection might have
caused a decrease in the PPI metabolism, which may
explain the high eradication rate of H. pylori in HCV-
infected patients. Azuma and colleagues [26] from Japan
observed that the cure rate of H. pylori after a 2-week
lansoprazole-based standard triple therapy in cirrhosis pa-
tients was 89.3% in the PP analysis, which was high
compared with 83.5% in the peptic ulcer group. However,
the authors claimed that it had resulted from the reduced
metabolism of clarithromycin in patients with liver
cirrhosis, especially those at the ChildePugh C stage. In
addition, a Korean study reported that the first-line H.
pylori eradication rates between liver cirrhosis patients and
CLD patients were 82.6% and 88.1%, respectively [27].
Importantly, H. pylori DNA has been identified in human
livers and has been implicated in CLD and liver cancer [28].
Therefore, it is worth performing more detailed studies in
this regard to further explore the influence of H. pylori
infection in CLD patients.
It is widely accepted that antibiotic resistance and pa-
tient compliance are the main factors affecting the
outcome of H. pylori eradication [29]. The non-CLD group
had more adverse events than the CLD group (9.2% vs. 1.5%,
p Z 0.003) in this study but the compliance rates were as
high as 99.3% and 99.6% in the CLD and non-CLD groups,
respectively. This could be due to the fact that these were
mild and did not markedly disturb the patients’ daily ac-
tivities. The other reason could be the possible side effects
of their medications and the importance of adhering to
their eradication therapy at the outpatient clinics.
Clinical factors significantly influencing the success of H.
pylori eradication other than antibiotics resistances and
compliance to medications are inconclusive. A Korean study
reported that female sex and smoking were relevant to the
failure of H. pylori eradication [30]. In our subgroup anal-
ysis, we found that more female patients failed to eradi-
cate H. pylori in the non-CLD group (89.5% vs. 78.5%,
pZ 0.001). In fact, there were more female patients in the
CLD group who failed to eradicate H. pylori, but this was
not statistically significant in this study (88.2% vs. 83.8%,
pZ 0.458). The cause is not fully understood so far. In one
study, females showed a higher prevalence of metronida-
zole resistance than males and this led to lower eradication
rates with metronidazole-containing regimens [31].
In this study, alcohol consumption was the significant
clinical factor influencing H. pylori eradication rate,
particularly in patients with CLD (p Z 0.022). Alcohol
consumption was reported to be associated with a small,
but not statistically significant, decrease in the odds of H.
pylori infection and it appeared to have an additive effect
in the triple eradication therapy [32]. However, there were
other studies showing that alcohol consumption was not
relevant to the success of H. pylori eradication [33,34].Subclinical insults such as alcohol ingestion to the stomach
that occur in daily life can potentially attract H. pylori.
Such subclinical insults not only slow the repair of any
existing damage, but may also provide an initiation site to
initiate the pathogenic sequence of stomach disease
caused by H. pylori [35]. Alcohol consumption in patients
with CLDs exacerbates the liver damage and leads to rapid
progression to hepatitis, fibrosis, and even hepatoma. Evi-
dence showed that ethanol exposure can potentiate the
suppressive effects of HCV on innate immunity, which ac-
tivates viral spread in the liver, and finally leads to im-
pairments in adaptive immunity [36]. Moreover, the first-
pass metabolism of ethanol is attenuated in patients with
H. pylori infection due to reduced alcohol dehydrogenase
activity in the inflamed gastric mucosa [37]. However, more
convincing evidence is needed to obtain more information
on this issue. Thus, further studies are mandatory in the
future.
There are some limitations in this study. First, it is a
retrospective study in a single medical center. Second, the
number of patients with cirrhosis is small, and thus sub-
group analysis according to the severity of cirrhosis could
not be conducted. Third, no information on antibiotic
resistance to H. pylori was available. H. pylori culture was
not routinely applied to patients before triple therapy.
Importantly, Liou and colleagues [38] reported that 14-day
standard triple therapy achieved over 90% of eradication
rates in Taiwan (PP analysis). Currently, in Taiwan, only the
expense of 7-day triple therapy is covered by the insurance
scheme according to the National Health Insurance policy.
We believe that the change to 14-day standard triple
therapy as the first-line eradication after the ongoing
Taiwan H. pylori consensus meeting will occur in near
future.
Conclusion
This study suggests that H. pylori eradication rates in pa-
tients with CLD may be comparable with non-CLD patients.
Alcohol consumption was the significant factor influencing
H. pylori eradication in patients with CLD. However, more
large-scale prospective studies are mandatory in future.References
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